Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

September 1, 2021 4:31 PM EDT

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS),... More